Assuntos
Humanos , Rinite Alérgica , Terapêutica , Lactococcus lactis , Plasma , Roxitromicina , Probióticos , Imunoterapia , Pacientes , JapãoRESUMO
Background: Proteus mirabilis poses a critical burden on the breeding industry, but no efficient vaccine is available for animals. Method: A recombinant Lactococcus lactis expressing the ompA of P. mirabilis was used to develop a vaccine. The mucosal and systemic immune responses of the recombinant vaccine were evaluated in mice after oral immunisation. The inhibition on P. mirabilis colonisation of vaccines was also determined. Moreover, Taishan Pinus massoniana pollen polysaccharides (TPPPS) were used as adjuvants to examine the immunomodulatory effects. Results: The pure recombinant L. lactis vaccine significantly induced the production of specific IgA and IgG, IL-2, IL-4, IFN-γ, and T lymphocyte proliferation, and the immunised mice exhibited significant resistance to P. mirabilis colonisation. Notably, the TPPPS adjuvant vaccines induced higher levels of immune responses than the pure L. lactis. Conclusions: The L. lactis as a vaccine vehicle combined with TPPPS adjuvant provides a feasible method for preventing P. mirabilis infection (AU)
No disponible
Assuntos
Animais , Proteus mirabilis/patogenicidade , Lactococcus lactis/imunologia , Vacinas Sintéticas/imunologia , Imunoterapia/métodos , Infecções por Proteus/prevenção & controle , Modelos Animais de Doenças , Tetraisopropilpirofosfamida/imunologia , Imunidade nas Mucosas/imunologiaRESUMO
No disponible
Assuntos
Humanos , Feminino , Adolescente , Lactococcus lactis/patogenicidade , Abscesso/microbiologia , Tireoidite Supurativa/microbiologia , Anorexia Nervosa/complicaçõesRESUMO
No disponible